VERITAS Study Evaluates Abbott Amulet 360 LAA Occluder in Nonvalvular AFib

February 13, 2026—Abbott recently announced positive early results from the VERITAS study evaluating its investigational Amulet 360 left atrial appendage (LAA) occluder in patients with nonvalvular atrial fibrillation (AFib). The data were presented in a late-breaking session at AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, according to the company.

The next-generation Amulet 360 device is designed to reduce stroke risk in patients with nonvalvular AFib by occluding the LAA, a common site of thrombus formation in this population. The device is approved for investigational use only in the United States.

In VERITAS, 93.9% of patients achieved complete LAA closure at 45 days, with no leaks > 3 mm. The prospective study enrolled 400 patients across 34 sites in the United States, Canada, and Europe. Implant success was reported in 99.8% of cases. The trial met its early safety and effectiveness benchmarks, with no complications such as additional surgery, stroke, or device-related thrombus reported through 7 days, according to Abbott. At 45 days, one device-related thrombus event was observed. The reported rate of pericardial effusion requiring drainage was 0.5%. No cases of heart tissue damage requiring surgery, intracranial bleeding, or device dislodgement were reported during the follow-up period.

Amulet 360 builds on Abbott’s Amplatzer Amulet LAA occluder, which has been available in the United States since 2021 and in Europe since 2013. Design modifications in the new device are intended to enhance how the implant conforms to a patient’s heart, according to the company.

“Abbott is committed to developing minimally invasive approaches that help doctors address AFib and prevent strokes, ensuring optimal safety and benefits for patients,” said Christopher Piorkowski, MD, Chief Medical Officer of Abbott’s electrophysiology business in the company’s press release. “With the next-generation Amulet 360, we are building upon the advancements we made with the introduction of our Amplatzer Amulet LAA occluder, which was the first device in the industry to both close the LAA and create a seal over it, allowing people to forgo blood-thinning medication.”

Follow-up for VERITAS is anticipated to conclude in 2027.